Maintenance treatment after induction therapy in non-small cell lung cancer: Latest evidence and clinical implications

Therapeutic Advances in Medical Oncology

Volumn 6, Issue 1, 2014, Pages 4-15

  Gentzler, Ryan D ^a   Patel, Jyoti D ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

cost benefit analysis; decision making; disease management; maintenance chemotherapy; metastatic; non small cell lung cancer; quality of life

Indexed keywords

ANALGESIC AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO;

CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; FINANCE; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HISTOLOGY; HUMAN; INDUCTION CHEMOTHERAPY; KARNOFSKY PERFORMANCE STATUS; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; META ANALYSIS (TOPIC); MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICIAN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84899093486     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834013510589     Document Type: Review

References (42)

1. Barlesi F. de Castro J. Dvornichenko V. Kim J. Pazzola A. Rittmeyer A. et al. (2011) AVAPERL (MO22089): final efficacy outcomes for patients (pts) with advanced non-squamous non-small cell lung cancer (NSNSCLC) randomised to continuation maintenance (MTC) with bevacizumab (Bev) or Bev + pemetrexed (Pem) after first-line (1L) Bev-cisplatin (Cis)-Pem treatment (TX). Eur J Cancer (Oxford) 47: 16.
2. Barlesi F. Scherpereel A. Rittmeyer A. Pazzola A. Ferrer Tur N. Kim J. et al. (2013) Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol, in press.
3. Belani C. Brodowicz T. Ciuleanu T. Krzakowski M. Yang S. Franke F. et al. (2012) Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study. Lancet Oncol 13: 292–299.
4. Belani C. Waterhouse D. Ghazal H. Ramalingam S. Bordoni R. Greenberg R. et al. (2010) Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 28: 7506.
5. Brodowicz T. Krzakowski M. Zwitter M. Tzekova V. Ramlau R. Ghilezan N. et al. (2006) Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 52: 155–163.
6. Cappuzzo F. Ciuleanu T. Stelmakh L. Cicenas S. Szczesna A. Juhasz E. et al. (2010) Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11: 521–529.
7. Ciuleanu T. Brodowicz T. Zielinski C. Kim J. Krzakowski M. Laack E. et al. (2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374: 1432–1440.
8. Ciuleanu T. Stelmakh L. Cicenas S. Miliauskas S. Grigorescu A. Hillenbach C. et al. (2012) Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol 13: 300–308.
9. Cullen M. Billingham L. Woodroffe C. Chetiyawardana A. Gower N. Joshi R. et al. (1999) Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 17: 3188–3194.
10. Emanuel E. Tanden N. Altman S. Armstrong S. Berwick D. de Brantes F. et al. (2012) A systemic approach to containing health care spending. N Engl J Med 367: 949–954.
11. Fidias P. Dakhil S. Lyss A. Loesch D. Waterhouse D. Bromund J. et al. (2009) Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 27: 591–598.
12. Garassino M. Martelli O. Bettini A. Floriani I. Copreni E. Lauricella C. et al. (2012) TAILOR: a phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (WT) EGFR. ASCO Meeting Abstracts 30: LBA7501.
13. Gerber D. Schiller J. (2013) Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea. J Clin Oncol 31: 1009–1020.
14. Goldie J. Coldman A. (1979) A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63: 1727–1733.
15. Gridelli C. Ciardiello F. Gallo C. Feld R. Butts C. Gebbia V. et al. (2012 a) First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol 30: 3002–3011.
16. Gridelli C. de Marinis F. Pujol J. Reck M. Ramlau R. Parente B. et al. (2012 b) Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol 7: 1713–1721.
17. Hanna N. Shepherd F. Fossella F. Pereira J. de Marinis F. von Pawel J. et al. (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22: 1589–1597.
18. Hollen P. Gralla R. Kris M. Cox C. Belani C. Grunberg S. et al. (1994) Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. psychometric assessment of the lung cancer symptom scale. Cancer 73: 2087–2098.
19. Juhasz E. Kim J. Klingelschmitt G. Walzer S. (2013) Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer. Eur J Cancer 49: 1205–1215.
20. Kabbinavar F. Miller V. Johnson B. O'Connor P. Soh C. and the Atlas Investigators (2010) Overall survival (OS) in Atlas, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (Chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 28: 7526.
21. Kim E. Hirsh V. Mok T. Socinski M. Gervais R. Wu Y. et al. (2008) Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372: 1809–1818.
22. Klein R. Wielage R. Muehlenbein C. Liepa A. Babineaux S. Lawson A. et al. (2010) Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol 5: 1263–1272.
23. Learn P. Bach P. (2010) PEM and the cost of multicycle maintenance. J Thorac Oncol 5: 1111–1112.
24. Lee C. Chertow G. Zenios S. (2009) An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard. Value Health 12: 80–87.
25. Matter-Walstra K. Joerger M. Kuhnel U. Szucs T. Pestalozzi B. Schwenkglenks M. (2012) Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care system. Value Health 15: 65–71.
26. Miller V. O'Connor P. Soh C. Kabbinavar F. for the Atlas Investigators (2009) A randomized, double-blind, placebo-controlled, phase IIIb trial (Atlas) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 27: LBA8002.
27. Non-Small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311: 899–909.
28. Patel J. Garon E. Govindan R. Reynolds C. Spigel D. Olsen M. et al. (2013) Exploratory analyses of efficacy and safety of pemetrexed (Pem) plus bevacizumab (Bev) and Bev alone as maintenance therapy (MT) in patients (Pts) with stage IIIb or IV nonsquamous non-small cell lung cancer (NS-NSCLC). ASCO Meeting Abstracts 31: 8012.
29. Patel J. Hensing T. Rademaker A. Hart E. Blum M. Milton D. et al. (2009) Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 27: 3284–3289.
30. Patel J. Socinski M. Garon E. Reynolds C. Spigel D. Hermann R. et al. (2012) A randomized, open-label, phase 3, superiority study of pemetrexed (Pem)+carboplatin (Cb)+bevacizumab (B) followed by maintenance Pem+B versus paclitaxel (Pac)+Cb+B followed by maintenance B in patients (Pts) with stage IIIb or IV non-squamous non-small cell lung cancer (NS-NSCLC). J Thoracic Oncol 7: S336, Abstract LBPL331.
31. Paz-Ares L. de Marinis F. Dediu M. Thomas M. Pujol J. Bidoli P. et al. (2013) PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol, in press.
32. Perol M. Chouaid C. Perol D. Barlesi F. Gervais R. Westeel V. et al. (2012) Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 30: 3516–3524.
33. Petrelli F. Borgonovo K. Cabiddu M. Barni S. (2011) Erlotinib as maintenance therapy in patients with advanced non-small cell lung cancer: a pooled analysis of three randomized trials. Anticancer Drugs 22: 1010–1019.
34. Pirker R. Pereira J. Szczesna A. von Pawel J. Krzakowski M. Ramlau R. et al. (2009) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373: 1525–1531.
35. Rittmeyer A. Scherpereel A. Gorbunova V. Gervais R. Vikstrom A. Chouaid C. et al. (2013) Effect of maintenance bevacizumab (Bev) plus pemetrexed (Pem) after first-line cisplatin/Pem/Bev in advanced nonsquamous non-small cell lung cancer (NSNSCLC) on overall survival (Os) of patients (Pts) on the AVAPERL (MO22089) phase III randomized trial. ASCO Meeting Abstracts 31: 8014.
36. Sandler A. Gray R. Perry M. Brahmer J. Schiller J. Dowlati A. et al. (2006) Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542–2550.
37. Scagliotti G. Parikh P. von Pawel J. Biesma B. Vansteenkiste J. Manegold C. et al. (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26: 3543–3551.
38. Schiller J. Harrington D. Belani C. Langer C. Sandler A. Krook J. et al. (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92–98.
39. Shepherd F. Rodrigues Pereira J. Ciuleanu T. Tan E. Hirsh V. Thongprasert S. et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123–132.
40. Spiro S. Rudd R. Souhami R. Brown J. Fairlamb D. Gower N. et al. (2004) Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 59: 828–836.
41. Zeng X. Peng L. Li J. Chen G. Tan C. Wang S. et al. (2013) Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system. Clin Ther 35: 54–65.
42. Zinner R. Ross H. Weaver R. Govindan R. Holden V. Chowhan N. et al. (2013) Randomized, open-label, phase III study of pemetrexed plus carboplatin (PEMC) followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab (PCB) Followed by maintenance bevacizumab in patients with advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 31: LBA8003.